The DOAC reversal agent andexanet has been shown to rapidly and markedly reduce anti-factor Xa activity in patients with acute major bleeding associated with the use of a factor Xa inhibitor. The final results of the ANNEXA-4 study, published in NEJM, also showed that “82% of patients had excellent or good haemostatic efficacy at 12 hours.” ...
DOAC reversal agent reduces anti-factor Xa activity
By Mardi Chapman
14 Feb 2019